{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:31:57Z","timestamp":1786980717795,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10495-023-01898-2","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T12:01:44Z","timestamp":1697544104000},"page":"121-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-\u03baB pathways"],"prefix":"10.1007","volume":"29","author":[{"given":"Jiawei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"issue":"4","key":"1898_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.euf.2023.03.017","volume":"9","author":"CD Gaffney","year":"2023","unstructured":"Gaffney CD, Katims A, D\u2019Souza N, Bjurlin MA, Matulewicz RS (2023) Bladder cancer carcinogens: opportunities for risk reduction. Eur Urol Focus 9(4):575\u2013578. https:\/\/doi.org\/10.1016\/j.euf.2023.03.017","journal-title":"Eur Urol Focus"},{"issue":"1","key":"1898_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96\u2013108. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.010","journal-title":"Eur Urol"},{"issue":"7","key":"1898_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2011.1142","volume":"306","author":"ND Freedman","year":"2011","unstructured":"Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306(7):737\u2013745. https:\/\/doi.org\/10.1001\/jama.2011.1142","journal-title":"JAMA"},{"issue":"9","key":"1898_CR4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/oem.58.9.590","volume":"58","author":"MP Zeegers","year":"2001","unstructured":"Zeegers MP, Swaen GM, Kant I, Goldbohm RA, van den Brandt PA (2001) Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands. Occup Environ Med 58(9):590\u2013596. https:\/\/doi.org\/10.1136\/oem.58.9.590","journal-title":"Occup Environ Med"},{"issue":"5","key":"1898_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD (2020) Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 70(5):404\u2013423. https:\/\/doi.org\/10.3322\/caac.21631","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1898_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00428-015-1739-2","volume":"466","author":"E Comp\u00e9rat","year":"2015","unstructured":"Comp\u00e9rat E, Larr\u00e9 S, Roupret M et al (2015) Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch 466(5):589\u2013594. https:\/\/doi.org\/10.1007\/s00428-015-1739-2","journal-title":"Virchows Arch"},{"key":"1898_CR7","unstructured":"APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/35673559\/. Accessed 1 Aug 2023"},{"key":"1898_CR8","unstructured":"NF-kB in development and progression of human cancer-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/15856292\/. Accessed 1 Aug 2023"},{"key":"1898_CR9","unstructured":"The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/33997176\/. Accessed 1 Aug 2023"},{"key":"1898_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","volume":"85","author":"R Ullah","year":"2022","unstructured":"Ullah R, Yin Q, Snell AH, Wan L (2022) RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol 85:123\u2013154. https:\/\/doi.org\/10.1016\/j.semcancer.2021.05.010","journal-title":"Semin Cancer Biol"},{"key":"1898_CR11","doi-asserted-by":"publisher","first-page":"119499","DOI":"10.1016\/j.lfs.2021.119499","volume":"278","author":"ER Asl","year":"2021","unstructured":"Asl ER, Amini M, Najafi S et al (2021) Interplay between MAPK\/ERK signaling pathway and MicroRNAs: a crucial mechanism regulating cancer cell metabolism and tumor progression. Life Sci 278:119499. https:\/\/doi.org\/10.1016\/j.lfs.2021.119499","journal-title":"Life Sci"},{"key":"1898_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.omto.2021.02.015","volume":"21","author":"HC Lin","year":"2021","unstructured":"Lin HC, Li J, Cheng DD et al (2021) Nuclear export protein CSE1L interacts with P65 and promotes NSCLC growth via NF-\u03baB\/MAPK pathway. Mol Ther Oncolytics 21:23\u201336. https:\/\/doi.org\/10.1016\/j.omto.2021.02.015","journal-title":"Mol Ther Oncolytics"},{"issue":"9","key":"1898_CR13","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, Mohammadian S, Vazini H et al (2018) Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 233(9):6425\u20136440. https:\/\/doi.org\/10.1002\/jcp.26429","journal-title":"J Cell Physiol"},{"key":"1898_CR14","unstructured":"A timeline of tumour-associated macrophage biology-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/36792751\/. Accessed 1 Aug 2023"},{"issue":"1","key":"1898_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2022.12.003","volume":"56","author":"X Zhang","year":"2023","unstructured":"Zhang X, Ji L, Li MO (2023) Control of tumor-associated macrophage responses by nutrient acquisition and metabolism. Immunity 56(1):14\u201331. https:\/\/doi.org\/10.1016\/j.immuni.2022.12.003","journal-title":"Immunity"},{"key":"1898_CR16","unstructured":"Metabolic regulation of macrophage polarization in cancer-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/31813459\/. Accessed 1 Aug 2023"},{"issue":"1","key":"1898_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5\u201329. https:\/\/doi.org\/10.3322\/caac.21254","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1898_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71\u201396. https:\/\/doi.org\/10.3322\/CA.2007.0010","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1898_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.23986","volume":"115","author":"E Scosyrev","year":"2009","unstructured":"Scosyrev E, Noyes K, Feng C, Messing E (2009) Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115(1):68\u201374. https:\/\/doi.org\/10.1002\/cncr.23986","journal-title":"Cancer"},{"issue":"1","key":"1898_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.juro.2008.03.045","volume":"180","author":"SA Strope","year":"2008","unstructured":"Strope SA, Montie JE (2008) The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol 180(1):31\u201337 discussion 37. https:\/\/doi.org\/10.1016\/j.juro.2008.03.045","journal-title":"J Urol"},{"key":"1898_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/03008880802325192","author":"RC Reulen","year":"2008","unstructured":"Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP (2008) A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl. https:\/\/doi.org\/10.1080\/03008880802325192","journal-title":"Scand J Urol Nephrol Suppl"},{"issue":"2","key":"1898_CR22","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/ijc.28022","volume":"133","author":"SE Daugherty","year":"2013","unstructured":"Daugherty SE, Lacey JV, Pfeiffer RM, Park Y, Hoover RN, Silverman DT (2013) Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP diet and health study. Int J Cancer 133(2):462\u2013472. https:\/\/doi.org\/10.1002\/ijc.28022","journal-title":"Int J Cancer"},{"issue":"1","key":"1898_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-023-00387-1","volume":"12","author":"T Steinfass","year":"2023","unstructured":"Steinfass T, Poelchen J, Sun Q et al (2023) Secretogranin II influences the assembly and function of MHC class I in melanoma. Exp Hematol Oncol 12(1):29. https:\/\/doi.org\/10.1186\/s40164-023-00387-1","journal-title":"Exp Hematol Oncol"},{"key":"1898_CR24","unstructured":"The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/23081990\/. Accessed 1 Aug 2023"},{"issue":"7844","key":"1898_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-3031-0","volume":"590","author":"EL Yap","year":"2021","unstructured":"Yap EL, Pettit NL, Davis CP et al (2021) Bidirectional perisomatic inhibitory plasticity of a Fos neuronal network. Nature 590(7844):115\u2013121. https:\/\/doi.org\/10.1038\/s41586-020-3031-0","journal-title":"Nature"},{"key":"1898_CR26","doi-asserted-by":"publisher","first-page":"110025","DOI":"10.1016\/j.intimp.2023.110025","volume":"118","author":"X Cheng","year":"2023","unstructured":"Cheng X, Zhang M, Xie Y et al (2023) Bone marrow-derived mesenchymal stem cells accelerate angiogenesis in pregnant experimentally induced deep venous thrombosis rat model via up-regulation of pro-angiogenic secretogranin II. Int Immunopharmacol 118:110025. https:\/\/doi.org\/10.1016\/j.intimp.2023.110025","journal-title":"Int Immunopharmacol"},{"key":"1898_CR27","unstructured":"SCG2 is a Prognostic biomarker associated with immune infiltration and macrophage polarization in colorectal cancer-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/35047505\/. Accessed 1 Aug 2023"},{"key":"1898_CR28","unstructured":"The prognostic value of secretogranin II and its impact on the immune microenvironment in patients with renal-cell carcinoma-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/37120376\/. Accessed 1 Aug 2023"},{"key":"1898_CR29","doi-asserted-by":"publisher","first-page":"873871","DOI":"10.3389\/fimmu.2022.873871","volume":"13","author":"S Weng","year":"2022","unstructured":"Weng S, Liu Z, Ren X et al (2022) SCG2: a prognostic marker that pinpoints chemotherapy and immunotherapy in colorectal cancer. Front Immunol 13:873871. https:\/\/doi.org\/10.3389\/fimmu.2022.873871","journal-title":"Front Immunol"},{"issue":"1","key":"1898_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12672-023-00737-9","volume":"14","author":"J Tan","year":"2023","unstructured":"Tan J, Zhong M, Hu Y et al (2023) Ritanserin suppresses acute myeloid leukemia by inhibiting DGK\u03b1 to downregulate phospholipase D and the Jak-Stat\/MAPK pathway. Discov Oncol 14(1):118. https:\/\/doi.org\/10.1007\/s12672-023-00737-9","journal-title":"Discov Oncol"},{"issue":"1","key":"1898_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cbf.3677","volume":"40","author":"Q Sun","year":"2022","unstructured":"Sun Q, Zhou Y, Xiong M, Chen Y, Tan WS, Cai H (2022) MEK1 activation enhances the ex vivo proliferation of haematopoietic stem\/progenitor cell. Cell Biochem Funct 40(1):79\u201389. https:\/\/doi.org\/10.1002\/cbf.3677","journal-title":"Cell Biochem Funct"},{"issue":"6","key":"1898_CR32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1898_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1898_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JWF, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234\u2013241. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033","journal-title":"Eur Urol"},{"issue":"5","key":"1898_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/bju.12601","volume":"114","author":"AB Smith","year":"2014","unstructured":"Smith AB, Deal AM, Woods ME et al (2014) Muscle-invasive bladder cancer: evaluating treatment and survival in the national cancer data base. BJU Int 114(5):719\u2013726. https:\/\/doi.org\/10.1111\/bju.12601","journal-title":"BJU Int"},{"issue":"1","key":"1898_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrurol.2012.219","volume":"10","author":"MS Soloway","year":"2013","unstructured":"Soloway MS (2013) Bladder cancer: lack of progress in bladder cancer\u2013what are the obstacles? Nat Rev Urol 10(1):5\u20136. https:\/\/doi.org\/10.1038\/nrurol.2012.219","journal-title":"Nat Rev Urol"},{"key":"1898_CR37","doi-asserted-by":"publisher","first-page":"107871","DOI":"10.1016\/j.pharmthera.2021.107871","volume":"226","author":"P Jain","year":"2021","unstructured":"Jain P, Kathuria H, Momin M (2021) Clinical therapies and nano drug delivery systems for urinary bladder cancer. Pharmacol Ther 226:107871. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107871","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1898_CR38","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00345-020-03474-8","volume":"39","author":"JL Pfail","year":"2021","unstructured":"Pfail JL, Katims AB, Alerasool P, Sfakianos JP (2021) Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. World J Urol 39(5):1319\u20131329. https:\/\/doi.org\/10.1007\/s00345-020-03474-8","journal-title":"World J Urol"},{"issue":"1","key":"1898_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O et al (2022) European association of urology guidelines on non-muscle-invasive bladder Cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"key":"1898_CR40","unstructured":"A tale of exosomes and their implication in cancer-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/37172650\/. Accessed 1 Aug 2023"},{"key":"1898_CR41","unstructured":"EMT\/MET plasticity in cancer and Go-or-grow decisions in quiescence: the two sides of the same coin?-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/37259089\/. Accessed 1 Aug 2023"},{"key":"1898_CR42","unstructured":"EMT transition states during tumor progression and metastasis-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/30594349\/. Accessed 1 Aug 2023"},{"issue":"4","key":"1898_CR43","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/med.21948","volume":"43","author":"HL Ang","year":"2023","unstructured":"Ang HL, Mohan CD, Shanmugam MK et al (2023) Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds. Med Res Rev 43(4):1141\u20131200. https:\/\/doi.org\/10.1002\/med.21948","journal-title":"Med Res Rev"},{"issue":"6","key":"1898_CR44","doi-asserted-by":"publisher","first-page":"e13423","DOI":"10.1111\/cpr.13423","volume":"56","author":"D Li","year":"2023","unstructured":"Li D, Xia L, Huang P et al (2023) Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in cancer metastasis: focusing on partial EMT and regulatory mechanisms. Cell Prolif 56(6):e13423. https:\/\/doi.org\/10.1111\/cpr.13423","journal-title":"Cell Prolif"},{"key":"1898_CR45","unstructured":"Anti-cancer natural products and their bioactive compounds inducing ER stress-mediated apoptosis: a review-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/30081573\/. Accessed 1 Aug 2023"},{"issue":"5","key":"1898_CR46","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","volume":"18","author":"D Bertheloot","year":"2021","unstructured":"Bertheloot D, Latz E, Franklin BS (2021) Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol 18(5):1106\u20131121. https:\/\/doi.org\/10.1038\/s41423-020-00630-3","journal-title":"Cell Mol Immunol"},{"key":"1898_CR47","unstructured":"Cell death, therapeutics, and the immune response in cancer-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/36841748\/. Accessed 1 Aug 2023"},{"key":"1898_CR48","unstructured":"Apoptosis in cancer: from pathogenesis to treatment-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/21943236\/. Accessed 1 Aug 2023"},{"issue":"2","key":"1898_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","volume":"21","author":"FJ Bock","year":"2020","unstructured":"Bock FJ, Tait SWG (2020) Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol 21(2):85\u2013100. https:\/\/doi.org\/10.1038\/s41580-019-0173-8","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1898_CR50","unstructured":"Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/31941155\/. Accessed 1 Aug 2023"},{"issue":"3","key":"1898_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/wsbm.1331","volume":"8","author":"S Mitchell","year":"2016","unstructured":"Mitchell S, Vargas J, Hoffmann A (2016) Signaling via the NF\u03baB system. Wiley Interdiscip Rev Syst Biol Med 8(3):227\u2013241. https:\/\/doi.org\/10.1002\/wsbm.1331","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"1898_CR52","unstructured":"Tumor associated macrophages and TAMs-based anti-tumor nanomedicines-PubMed.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/34292673\/. Accessed 1 Aug 2023"},{"key":"1898_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2023.03.008","author":"J Liu","year":"2023","unstructured":"Liu J, Cao X (2023) Glucose metabolism of TAMs in tumor chemoresistance and metastasis. Trends Cell Biol. https:\/\/doi.org\/10.1016\/j.tcb.2023.03.008","journal-title":"Trends Cell Biol"},{"issue":"7","key":"1898_CR54","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399\u2013416. https:\/\/doi.org\/10.1038\/nrclinonc.2016.217","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-023-01898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-023-01898-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-023-01898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T10:20:21Z","timestamp":1706696421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-023-01898-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":54,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1007\/s10495-023-01898-2","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"22 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}